Skip to main content

Advertisement

SpringerLink
Log in

Treatment of metastatic breast cancer: looking towards the future

  • Review
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The armamentarium for the treatment of metastatic breast cancer is increasing with the introduction of newer chemotherapeutic agents and the development of molecular targeted therapies. The clinical utility of anthracyclines in advanced breast cancer has been limited by significant adverse events; therefore the taxanes are increasingly used in the metastatic setting. Trastuzumab with a taxane as first-line therapy is now standard of care for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Other targeted therapies, including the antiangiogenesis agents such as bevacizumab, are being investigated both as monotherapy and in combination regimens. While the number of available agents is growing rapidly, challenges remain concerning appropriate dose, schedule, treatment duration and management of drug resistance. This paper reviews recent data regarding the established and investigational medical treatments for endocrine-refractory metastatic breast cancer, and presents treatment recommendations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mouridsen H, Gershanovich M, Sun Y et al (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21(11):2101–2109

    Article  PubMed  CAS  Google Scholar 

  2. Nabholtz JM, Bonneterre J, Buzdar A et al (2003) Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 39(12):1684–1689

    Article  PubMed  CAS  Google Scholar 

  3. Nabholtz JM, Buzdar A, Pollak M et al (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18(22):3758–3767

    PubMed  CAS  Google Scholar 

  4. Batist G, Ramakrishnan G, Rao CS et al (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19(5):1444–1454

    PubMed  CAS  Google Scholar 

  5. Harris L, Batist G, Belt R et al (2002) Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94(1):25–36

    Article  PubMed  CAS  Google Scholar 

  6. Conlin AK, Seidman AD (2007) Taxanes in breast cancer: an update. Curr Oncol Rep 9(1):22–30

    Article  PubMed  CAS  Google Scholar 

  7. Seidman A, Berry D, Cirrincione C et al (2004) CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3 h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol 22(14S); Abstract 512

  8. Harvey V, Mouridsen H, Semiglazov V et al (2006) Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 24(31):4963–4970

    Article  PubMed  CAS  Google Scholar 

  9. John TA, Vogel SM, Tiruppathi C et al (2003) Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol 284(1):L187–L196

    CAS  Google Scholar 

  10. Gradishar WJ, Krasnojon D, Cheporov S et al (2006) A randomized phase 2 trial of qw or q3w ABI-007 (ABX) vs. q3w solvent-based docetaxel (TXT) as first-line therapy in metastatic breast cancer (MBC). Breast Cancer Res Treat 100(Suppl 1):S21; Abstract 46

    Google Scholar 

  11. O’Shaughnessy J, Nag S, Calderillo-Ruiz G et al (2003) Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracylcine pretreated metastatic breast cancer (MBC): interim results of a global phase III study. Proc Am Soc Clin Oncol 22; Abstract 25

  12. Miles D, Vukelja S, Moiseyenko V et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812–2823

    Article  PubMed  CAS  Google Scholar 

  13. Albain K, Nag S, Calderillo-Ruiz G et al (2004) Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. J Clin Oncol 22(14S); Abstract 510

    Google Scholar 

  14. Miles D, Vukelja S, Moiseyenko V et al (2004) Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clin Breast Cancer 5(4):273–278

    Article  PubMed  CAS  Google Scholar 

  15. Sledge GW, Neuberg D, Bernardo P et al (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21(4):588–592

    Article  PubMed  Google Scholar 

  16. Alba E, Martin M, Ramos M et al (2004) Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol 22(13):2587–2593

    Article  PubMed  CAS  Google Scholar 

  17. Baldini E, Prochilo T, Salvadori B et al (2004) Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety. Brit J Cancer 91(1):45–49

    Article  PubMed  CAS  Google Scholar 

  18. Cresta S, Grasselli G, Mansutti M et al (2004) A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer. Ann Oncol 15(3):433–439

    Article  PubMed  CAS  Google Scholar 

  19. Thomas ES, Gomez HL, Li RK et al (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25(33):5210–5217

    Article  PubMed  CAS  Google Scholar 

  20. Perez EA, Lerzo G, Pivot X et al (2007) Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 25(23):3407–3414

    Article  PubMed  CAS  Google Scholar 

  21. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 344:783–792

    Article  PubMed  CAS  Google Scholar 

  22. Marty M, Cognetti F, Maraninchi D et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23:4265–4274

    Article  PubMed  CAS  Google Scholar 

  23. Marty M, Cognetti F, Maraninchi D et al (2006) Superior long-term survival benefits of trastuzumab plus docetaxel compared to docetaxel alone in patients with HER2-positive metastatic breast cancer: patients surviving more than 4 years in the M77001 study. Breast Cancer Res Treat 100(Suppl 1):S103; Abstract 2067

    Google Scholar 

  24. Pegram MD, Pienkowski T, Northfelt DW et al (2004) Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 96:759–769

    Article  PubMed  CAS  Google Scholar 

  25. Slamon D, Yeon CH, Pienkowski T et al (2004) Survival analysis from two open-label non-randomized phase II trials of trastuzumab (H) combined with docotaxel (T) and platinums (C, cisplatin or carboplatin) (TCH) in women with HER2+ advanced breast cancer (ABC). J Clin Oncol 22(14S); Abstract 642

  26. Burris H 3rd, Yardley D, Jones S et al (2004) Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 22:1621–1629

    Article  PubMed  CAS  Google Scholar 

  27. Perez EA, Suman VJ, Rowland KM et al (2005) Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer 6:425–432

    Article  PubMed  CAS  Google Scholar 

  28. Robert N, Leyland-Jones B, Asmar L et al (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24:2786–2792

    Article  PubMed  CAS  Google Scholar 

  29. Pegram M, Forbes J, Pienkowski T et al (2007) BCIRG 007: first overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). J Clin Oncol 25(18S):968S; Abstract LBA1008

    Google Scholar 

  30. Mackey J, Kaufman B, Clemens M et al (2006) Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Breast Cancer Res Treat 100(Suppl 1):S5; Abstract 3

    Google Scholar 

  31. Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. New Engl J Med 355(26):2733–2743

    Article  PubMed  CAS  Google Scholar 

  32. Force T, Krause DS, Van Etten RA (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev 7(5):332–344

    CAS  Google Scholar 

  33. Kerkela R, Grazette L, Yacobi R et al (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12(8):908–916

    Article  PubMed  CAS  Google Scholar 

  34. Perez E, Byrne J, Hammond I et al (2006) Cardiac safety experience in 3127 patients (pts) treated with lapatinib. Ann Oncol 17(Suppl 9):ix70; Abstract 1420

    Google Scholar 

  35. Ciardiello F, Caputo R, Bianco R et al (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053–2063

    PubMed  CAS  Google Scholar 

  36. Yang SX, Simon RM, Tan AR et al (2005) Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer. Clin Cancer Res 11:6226–6232

    Article  PubMed  CAS  Google Scholar 

  37. Ciardiello F, Troiani T, Caputo F et al (2006) Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Brit J Cancer 94:1604–1609

    PubMed  CAS  Google Scholar 

  38. Rakha EA, El-Rehim DA, Paish C et al (2006) Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 42(18):3149–3156

    Article  PubMed  CAS  Google Scholar 

  39. Banerjee S, Reis-Filho JS, Ashley S et al (2006) Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol 59(7):729–735

    Article  PubMed  CAS  Google Scholar 

  40. Lakhani SR, Reis-Filho JS, Fulford L et al (2005) Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11(14):5175–5180

    Article  PubMed  CAS  Google Scholar 

  41. Modi S, D’Andrea G, Norton L et al (2006) A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clin Breast Cancer 7(3):270–277

    Article  PubMed  CAS  Google Scholar 

  42. Cobleigh MA, Langmuir VK, Sledge GW et al (2003) A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30:117–124

    Article  PubMed  CAS  Google Scholar 

  43. Sweeney CJ, Miller KD, Sissons SE et al (2001) The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 61:3369–3372

    PubMed  CAS  Google Scholar 

  44. Miller KD, Chap LI, Holmes FA et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792–799

    Article  PubMed  CAS  Google Scholar 

  45. Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New Engl J Med 357(26):2666–2676

    Article  PubMed  CAS  Google Scholar 

  46. Ramaswamy B, Elias AD, Kelbick NT et al (2006) Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 12:3124–3129

    Article  PubMed  CAS  Google Scholar 

  47. Perez EA, Hillman DW, Kugler JW et al (2006) North Central cancer treatment group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. Breast Cancer Res Treat 100(Suppl 1); Abstract 2069

  48. Link JS, Waisman JR, Jacobs CI (2006) Bevacizumab (avastin) and albumin bound paclitaxel (abraxane) treatment in metastatic breast cancer. Breast Cancer Res Treat 100(Suppl 1):S69; Abstract 1095

    Google Scholar 

  49. Sledge G, Miller K, Moisa C, Gradishar W (2007) Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer. J Clin Oncol 25(18S):35S; Abstract 1013

    Google Scholar 

  50. Muss HB, Case LD, Richards F 2nd et al (1991) Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. New Engl J Med 325(19):1342–1348

    PubMed  CAS  Google Scholar 

  51. Gennari A, Amadori D, De Lena M et al (2006) Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol 24(24):3912–3918

    Article  PubMed  CAS  Google Scholar 

  52. Coates A, Gebski V, Bishop JF et al (1987) Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. New Engl J Med 317(24):1490–1495

    PubMed  CAS  Google Scholar 

  53. Konecny GE, Meng YG, Untch M et al (2004) Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 10(5):1706–1716

    Article  PubMed  CAS  Google Scholar 

  54. Pegram M, Chan D, Dichmann RA et al (2006) Phase II combined biological therapy targeting the HER2-proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HEr2-amplified breast cancer. Breast Cancer Res Treat 100(Suppl 1):S28; Abstract 301

    Google Scholar 

  55. Gomez H, Chavez M, Doval D et al (2005) A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer. J Clin Oncol 23(16S); Abstract 3046

Download references

Author information

Authors and Affiliations

  1. Mayo Clinic, 4500 San Pablo Rd., Jacksonville, FL, 32224, USA

    Surabhi Amar, Vivek Roy & Edith A. Perez

Authors
  1. Surabhi Amar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vivek Roy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edith A. Perez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Surabhi Amar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Amar, S., Roy, V. & Perez, E.A. Treatment of metastatic breast cancer: looking towards the future. Breast Cancer Res Treat 114, 413–422 (2009). https://doi.org/10.1007/s10549-008-0032-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-008-0032-3

Keywords

Search

Navigation